Automated Cell Therapy Manufacturing Platforms Market Size, Trend, Forecast Report 2026 to 2035

What is Automated Cell Therapy Manufacturing Platforms Market Size?

Automated Cell Therapy Manufacturing Platforms Market is estimated tog grow at a 19.5% CAGR during the forecast period for 2026 to 2035.

Automated Cell Therapy Manufacturing Platforms Market Size, Share & Trends Analysis Distribution by Offering (Instruments & Hardware Systems, Consumables, Cassettes & Process Kits, Software & Digital Orchestration, Services), By Platform Architecture (End-to-End Closed / Integrated Platforms, Modular Unit-Operation Instrument Suites, Robotic Orchestration Platforms, Point-of-Care / Decentralised Units, iPSC & Adherent-Cell Automation Systems), By Manufacturing Unit Operation (Cell Isolation & Selection, Activation, Transduction & Gene-Editing, Expansion & Bioreactor Culture, Wash, Concentration & Formulation, Fill–Finish, In-Process Analytics & Quality Control), By Therapy Modality (CAR-T-Cell Therapies, TCR-T & TIL Therapies, Regulatory T-Cell (Treg) Therapies, CAR-NK & NK-Cell Therapies, HSPC & Gene-Modified Stem-Cell Therapies, iPSC-Derived Allogeneic Therapies, Other Modalities (MSC, VST, Exosome & Emerging)), By Therapy Sourcing Model (Autologous Manufacturing, Allogeneic Manufacturing) and Segment Forecasts, 2026 to 2035

Cell therapy manufacturing is the controlled sequence of processes used to produce therapeutic cells for clinical and commercial application. Key steps typically include cell isolation and selection, activation, genetic modification where required, expansion, washing, formulation and final filling or cryopreservation. These operations must maintain cell viability, identity, purity and consistency while meeting strict quality and regulatory requirements. Processes can be performed on individual instruments or within integrated systems that combine multiple steps into a closed or semi-closed workflow.

The automated cell therapy manufacturing platforms market covers the instruments, integrated systems, robotic solutions, single-use consumables, software and related services that automate these workflows. Automation aims to reduce manual handling, improve process consistency, lower contamination risk and support scalable, compliant production.

These platforms support a range of cell therapy types, including CAR-T, TCR-T, tumour-infiltrating lymphocytes (TIL), regulatory T cells (Treg), natural killer (NK) cells and stem cell therapies. They are used for both autologous manufacturing, which processes a patient’s own cells, and allogeneic manufacturing, which uses donor-derived or off-the-shelf cell products. Main users include biopharmaceutical and biotechnology companies, contract development and manufacturing organisations (CDMOs), and academic or hospital-based manufacturing centres.
The market includes end-to-end closed manufacturing systems, modular platforms focused on specific process steps, robotic automation solutions, and specialised systems for induced pluripotent stem cell (iPSC) and adherent cell processing. Rising clinical and commercial demand for cell therapies continues to increase the need for reliable, scalable and regulatory-ready automated manufacturing technologies.

Competitive Landscape

Which are the Leading Players in the Automated Cell Therapy Manufacturing Platforms Market?

• Octane Medical Group
• Miltenyi Biotec
• Cellares
• Ori Biotech
• Cytiva
• Terumo BCT
• Thermo Fisher Scientific
• Sartorius
• Wilson Wolf / ScaleReady
• Adva Biotechnology
• Multiply Labs
• Fresenius Kabi
• Cellular Origins
• MaxCyte
• Cellino Biotech
• Applied Cells
• Sinfonia Technology
• Celltrio
• Cellistic
• CellFE

Market Dynamics

Driver

Increasing Demand for Cell and Gene Therapies

The clinical development and commercialisation of cell and gene therapies (particularly CAR-T, TCR-T, TIL and stem cell therapies) is driving the need for automated cell therapy manufacturing platforms. The therapies themselves are inherently complex, multi-stage processes involving cell isolation, activation, genetic modification, expansion and formulation. As more cell therapies move through the clinic and into commercialisation, there is a growing requirement for automated and integrated manufacturing platforms to provide a standardised manufacturing process, ensure product quality and enable the transition from small clinical scale manufacturing to larger commercial scale manufacturing.

Restrain/Challenge

High Cost of Automated Manufacturing Platforms

The high cost of developing, implementing and running automated cell therapy manufacturing platforms is a significant barrier to the market. The platforms themselves are expensive to build and require specialist instrumentation, robotics, single use consumables, software integration and GMP infrastructure to support the complex cell processing operations. There are also significant costs associated with platform installation, process validation, regulatory compliance and training of personnel. These costs can be prohibitive and will be a major barrier to adoption for smaller and emerging biotechs, academic institutions and facilities with very limited manufacturing budgets. This in turn will likely slow the rate of uptake of automated cell therapy manufacturing.

Cloud / SaaS segment Segment is Expected to Drive the Automated Cell Therapy Manufacturing Platforms Market

Instruments and hardware systems is forecasted to dominate the global automated cell therapy manufacturing platforms market. This market segment encompasses automated end-to-end manufacturing platforms, modular unit operation instruments, and robotic orchestration systems that are used at all key stages in cell processing such as isolation, activation, genetic modification, expansion, washing, and formulation of cells. These systems make up the fundamental hardware of automated cell therapy manufacturing platforms, which, along with their importance in production processes and relatively expensive equipment, is likely to ensure their dominance in the market.

Point-of-Care / Decentralised Units Segment is Growing at the Highest Rate in the Automated Cell Therapy Manufacturing Platforms Market

The point-of-care / decentralised units segment is expected to be the fastest growing in the automated cell therapy manufacturing platforms market. This is underpinned by the continued move towards decentralised manufacturing, particularly in the area of autologous cell therapies (such as CAR-T) where manufacturing at or near the point of care can facilitate the patient specific manufacturing process and reduce the need for centralised manufacturing.

Why North America Led the Automated Cell Therapy Manufacturing Platforms Market?

North America is expected to lead the market for automation platforms in the manufacturing of cell therapies due to the presence of a well-developed biotech and pharmaceutical industry in the region along with a strong manufacturing infrastructure for cell therapies and solid clinical research capabilities in the region. The United States is one of the key factors contributing to regional demand with a large number of companies in the region working in the development of cell therapies. There are also several contract development and manufacturing organizations (CDMOs) and key providers of these platforms such as Cellares, Miltenyi Biotec, and Thermo Fisher Scientific.

Key Development

November 2026: Octane Biotech and Currus Biologics completed the automation of CUR-001 manufacturing using Octane’s Cocoon Platform, establishing a closed process to support consistent clinical production. The milestone follows FDA clearance of Currus’ IND application in September 2026, enabling a Phase 1 trial in patients with advanced mesothelin-positive solid tumours, with first-patient dosing expected in early 2027. CUR-001 combines an autologous mesothelin-targeting CAR-T therapy with a BEAT bispecific antibody to address challenges associated with CAR-T treatment of solid tumours.

Automated Cell Therapy Manufacturing Platforms Market Report Scope: